Table 2.
Response rates and survival according to CAR T product in matched populations using PSM and IPTW approachesa
| PSM | IPTW | |||||
|---|---|---|---|---|---|---|
| axi-cel n = 209 | tisa-cel n = 209 | P | axi-cel | tisa-cel | P | |
| Response rate | ||||||
| ORR% (95% CI) | 80.4 (74.3–85.5) | 66.0 (59.2–72.4) | <0.001 | 78.5 (75.3–81.6) | 62.8 (59.2–66.3) | <0.001 |
| CRR% (95% CI) | 60.3 (53.3–67.0) | 42.1 (35.3–49.1) | <0.001 | 60.1 (56.4–63.8) | 42.0 (38.3–45.6) | <0.001 |
| Survival | ||||||
| PFS% at 1 year (95% CI) | 46.6 (38.5–54.3) | 33.2 (25.7–40.8) | 0.0003 | 44.5 (38.7–50.1) | 34.7 (26.2–43.3) | 0.0005 |
| HR (95% CI) | 0.61 (0.46–0.79) | 1 (ref) | 0.66 (0.53–0.82) | 1 (ref) | ||
| DOR% at 1 year (95% CI) | 53.8 (44.7–62.1) | 41.8 (31.3–51.9) | 0.106 | 51.0 (44.4–57.1) | 46.0 (33.0–58.0) | 0.482 |
| HR (95% CI) | 0.75 (0.53–1.06) | 1 (ref) | 0.81 (0.60–1.08) | 1 (ref) | ||
| OS% at 1 year (95% CI) | 63.5 (55.0–70.8) | 48.8 (39.7–57.2) | 0.0072 | 61.2 (55.1–66.6) | 48.3 (37.1–58.5) | 0.011 |
| HR (95% CI) | 0.63 (0.45–0.88) | 1 (ref) | 0.71 (0.54–0.93) | 1 (ref) | ||
aThe response was assessed according to the local investigators per Lugano 2014 criteria, and the best response throughout patient follow-up was reported.